SIDDHARTH KAUL
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- BRIDGETON, MO
- NPI
- 1245493402
- Received
- $442,011 in 994 records, 2019 to 2025 ($386,826 general, $55,185 research)
- As principal investigator
- $5,315,663 of research payments to others in 283 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 122 | $57,590 |
| 2024 | General payment | 164 | $28,454 |
| 2023 | General payment | 153 | $46,653 |
| 2023 | Research payment | 2 | $1,593 |
| 2022 | General payment | 148 | $65,475 |
| 2022 | Research payment | 2 | $5,674 |
| 2021 | General payment | 218 | $114,831 |
| 2020 | General payment | 111 | $33,058 |
| 2020 | Research payment | 3 | $5,472 |
| 2019 | General payment | 68 | $40,762 |
| 2019 | Research payment | 3 | $42,445 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 136 | $326,718 |
| Research payment | 10 | $55,185 |
| Food and Beverage | 790 | $21,078 |
| Compensation for serving as faculty or as a speaker for a medical education program | 20 | $18,190 |
| Travel and Lodging | 26 | $13,275 |
| Honoraria | 4 | $6,525 |
| Consulting Fee | 2 | $982 |
| Education | 6 | $55 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2025 | |
| 2025-12-17 | Neurocrine BioSciences, Inc. | $19 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-17 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-17 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-11 | PFIZER INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-09 | PFIZER INC. | $29 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-05 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-04 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-12-04 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-04 | Axsome Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-12-03 | Neurocrine BioSciences, Inc. | $33 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-19 | Axsome Therapeutics, Inc. | $2,025 | Honoraria | Cash or cash equivalent | Symbravo Drug, Neurology | 2025 | |
| 2025-11-19 | Axsome Therapeutics, Inc. | $83 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-11-18 | PFIZER INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-11-18 | PFIZER INC. | $3,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-11-18 | Eisai Inc. | $800 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-11-13 | ABBVIE INC. | $127 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-11-13 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-11-12 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-11-06 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-29 | PFIZER INC. | $118 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-23 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-14 | Neurocrine BioSciences, Inc. | $14 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-10-08 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | VYALEV Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | PFIZER INC. | $18 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2025 | |
| 2025-09-30 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2025 | |
| 2025-09-29 | Axsome Therapeutics, Inc. | $1,350 | Honoraria | Cash or cash equivalent | Symbravo Drug, Neurology | 2025 | |
| 2025-09-24 | Neurocrine BioSciences, Inc. | $21 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-24 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-09-24 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-09-18 | Eisai Inc. | $1,000 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-09-18 | Eisai Inc. | $400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-09-18 | Eisai Inc. | $121 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-09-03 | Neurocrine BioSciences, Inc. | $30 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-15 | Neurocrine BioSciences, Inc. | $20 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-08-15 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-12 | ABBVIE INC. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-12 | ABBVIE INC. | $960 | Travel and Lodging | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-12 | ABBVIE INC. | $74 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-12 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-11 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-11 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-01 | Axsome Therapeutics, Inc. | $11 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-07-30 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-30 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-29 | Axsome Therapeutics, Inc. | $2,025 | Honoraria | Cash or cash equivalent | Symbravo Drug, Neurology | 2025 | |
| 2025-07-29 | Axsome Therapeutics, Inc. | $79 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-07-23 | Axsome Therapeutics, Inc. | $1,125 | Honoraria | Cash or cash equivalent | Symbravo Drug, Neurology | 2025 | |
| 2025-07-23 | Neurocrine BioSciences, Inc. | $23 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-06-30 | Axsome Therapeutics, Inc. | $100 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-06-25 | Merck Sharp & Dohme LLC | $32 | Food and Beverage | In-kind items and services | Biological, NEUROSCIENCE | 2025 | |
| 2025-06-25 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-24 | Merck Sharp & Dohme LLC | $35 | Food and Beverage | In-kind items and services | Biological, NEUROSCIENCE | 2025 | |
| 2025-06-16 | Axsome Therapeutics, Inc. | $23 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-06-05 | Neurocrine BioSciences, Inc. | $18 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-28 | ABBVIE INC. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-05-22 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-05-22 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-05-22 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-05-16 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-14 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-14 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-09 | Eisai Inc. | $182 | Consulting Fee | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-05-08 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-08 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-05-05 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-02 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-05-01 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-04-29 | ABBVIE INC. | $2,756 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-04-29 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-04-24 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-04-22 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-04-22 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-04-18 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-04-17 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-04-16 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-04-16 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-04-16 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-04-10 | Neurocrine BioSciences, Inc. | $89 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-10 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-04-09 | Neurocrine BioSciences, Inc. | $18 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-07 | Eisai Inc. | $1,350 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-04-03 | Eisai Inc. | $2,190 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-04-03 | Eisai Inc. | $912 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-04-03 | Eisai Inc. | $123 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-04-03 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-04-02 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $630 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $326 | Travel and Lodging | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $69 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $59 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-29 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-28 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-27 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-03-25 | ABBVIE INC. | $93 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2025 | |
| 2025-03-20 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-03-20 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2025 | |
| 2025-03-19 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-19 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-13 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-03-12 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-03-12 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-06 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-03-05 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-03-04 | Neurocrine BioSciences, Inc. | $20 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-02-27 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-02-24 | Neurocrine BioSciences, Inc. | $19 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-02-20 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-02-06 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-01-31 | Eisai Inc. | $1,036 | Travel and Lodging | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-30 | Eisai Inc. | $1,095 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-30 | Eisai Inc. | $912 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-30 | Eisai Inc. | $49 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-30 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-01-29 | Eisai Inc. | $730 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2025 | |
| 2025-01-24 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-01-23 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-01-17 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | OCTAGAM IMMUNE GLOBULIN (HUMAN) Drug, IMMUNOLOGY | 2025 | |
| 2025-01-15 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-14 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-01-09 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-09 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2024-12-31 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-12-19 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-12-12 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-12-11 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-12-06 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-12-06 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-12-05 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-12-04 | Neurocrine BioSciences, Inc. | $12 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-12-04 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-12-04 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-12-04 | Neurocrine BioSciences, Inc. | $7 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-11-22 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-21 | Neurocrine BioSciences, Inc. | $20 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-11-21 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-19 | ABBVIE INC. | $3,675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-11-15 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-14 | Eisai Inc. | $1,095 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-11-14 | Eisai Inc. | $912 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-11-14 | Eisai Inc. | $36 | Food and Beverage | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-11-14 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-07 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-11-06 | Eisai Inc. | $912 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-11-06 | Eisai Inc. | $365 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | Leqembi Drug, Neurology | 2024 | |
| 2024-10-31 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-10-31 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-10-28 | ABBVIE INC. | $102 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-10-25 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-10-24 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-10-23 | TG Therapeutics, Inc. | $135 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2024 | |
| 2024-10-22 | ABBVIE INC. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-10-18 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-16 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-10-11 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-10 | Neurocrine BioSciences, Inc. | $132 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-10-10 | Celgene Corporation | $18 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-10-10 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-10-08 | ABBVIE INC. | $109 | Food and Beverage | In-kind items and services | BOTOX Biological, NEUROSCIENCE | 2024 | |
| 2024-10-04 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-03 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-10-01 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-09-27 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-09-20 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-09-16 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-09-13 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-09-12 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-09-09 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-09-06 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-08-30 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-08-16 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-08-09 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-08-09 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-08-09 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-08-02 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-08-02 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-08-02 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-08-01 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-07-19 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-07-19 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-07-19 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-07-19 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-07-15 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-07-12 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-07-12 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-07-10 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-06-28 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-06-28 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-06-28 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-06-27 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-06-25 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-06-21 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-06-21 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-06-14 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-06-14 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-06-14 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-06-11 | PFIZER INC. | $10 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-06-07 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-06-07 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2024 | |
| 2024-06-04 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 |
The latest 200 records of 994.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | PFIZER INC. | CLINICAL RESEARCH PROFESSIONALS LLC | $35,390 | AN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY TOLERAB | 2025 |
| 2025-12-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $1,287 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-12-11 | PFIZER INC. | CLINICAL RESEARCH PROFESSIONALS LLC | $18,800 | AN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY TOLERAB | 2025 |
| 2025-12-04 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $5,000 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-11-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $412 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-11-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $168 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-11-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $385 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-11-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,120 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-11-25 | PFIZER INC. | CLINICAL RESEARCH PROFESSIONALS LLC | $14,457 | AN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY TOLERAB | 2025 |
| 2025-09-26 | PFIZER INC. | CLINICAL RESEARCH PROFESSIONALS LLC | $10,721 | AN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY TOLERAB | 2025 |
| 2025-09-12 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $980 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-09-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $7,938 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-09-09 | PFIZER INC. | CLINICAL RESEARCH PROFESSIONALS LLC | $20,100 | AN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO INVESTIGATE THE SAFETY TOLERAB | 2025 |
| 2025-08-14 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $6,756 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-12 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $54 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $770 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,120 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,015 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,225 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $56 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $490 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $315 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $1,881 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $210 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $1,570 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $1,594 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-08-07 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $482 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-31 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,120 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-31 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $90 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-31 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $1,429 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-31 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $750 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-31 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $565 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-22 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $20,162 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $102 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $90 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $350 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $3,178 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $385 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $770 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $70 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $1,200 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $950 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $858 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $1,500 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $412 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $168 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $280 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $105 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-07-10 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $37,080 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-06-26 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $1,500 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-06-19 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $303 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-06-05 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,553 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-06-02 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $1,755 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-06-02 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $2,651 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-05-05 | Eli Lilly and Company | CLINICAL RESEARCH PROFESSIONALS LLC | $3,023 | ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-04-28 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $9,402 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-04-10 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $500 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-04-10 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $780 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-04-10 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $780 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-04-10 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $500 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-03-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $343 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-03-19 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,120 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-03-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $2,656 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-03-06 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $7,000 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-26 | Ipsen Innovation | Clinical Research Professionals | $500 | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Eva | 2025 |
| 2025-02-26 | Ipsen Innovation | Clinical Research Professionals | $1,250 | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Eva | 2025 |
| 2025-02-26 | Ipsen Innovation | Clinical Research Professionals | $2,000 | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Eva | 2025 |
| 2025-02-26 | Ipsen Innovation | Clinical Research Professionals | $500 | A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Eva | 2025 |
| 2025-02-25 | Eli Lilly and Company | CLINICAL RESEARCH PROFESSIONALS LLC | $1,395 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2025 |
| 2025-02-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $133 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $210 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $412 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $503 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-25 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $980 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-25 | Eli Lilly and Company | CLINICAL RESEARCH PROFESSIONALS LLC | $436 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-02-24 | Ipsen Innovation | Clinical Research Professionals | $1,250 | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evalu | 2025 |
| 2025-02-24 | GlaxoSmithKline, LLC. | CLINICAL RESEARCH PROFESSIONALS LLC | $10,663 | A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE | 2025 |
| 2025-02-24 | Ipsen Innovation | Clinical Research Professionals | $2,067 | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evalu | 2025 |
| 2025-02-24 | Ipsen Innovation | Clinical Research Professionals | $500 | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evalu | 2025 |
| 2025-02-24 | Ipsen Innovation | Clinical Research Professionals | $500 | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evalu | 2025 |
| 2025-02-24 | Ipsen Innovation | Clinical Research Professionals | $2,000 | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evalu | 2025 |
| 2025-02-20 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $266 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-20 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $105 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-20 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $90 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-20 | Ipsen Innovation | Clinical Research Professionals | $2,067 | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evalu | 2025 |
| 2025-02-20 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $420 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-20 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $280 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-18 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,120 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $336 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $133 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $910 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $112 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $168 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $565 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $196 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-11 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $503 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-05 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $4,120 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-02-04 | Eli Lilly and Company | CLINICAL RESEARCH PROFESSIONALS LLC | $17,788 | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 |
| 2025-01-29 | H. Lundbeck A S | CLINICAL RESEARCH PROFESSIONALS INC | $2,948 | INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE P | 2025 |
| 2025-01-27 | Eli Lilly and Company | CLINICAL RESEARCH PROFESSIONALS LLC | $19,988 | A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DEC | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bridgeton, MO, county St. Louis County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Bridgeton, MO | County St. Louis County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 11,369 | 995,569 | 6,191,814 |
| Population, 2020 census P1 | 11,445 | 1,004,125 | 6,154,913 |
| Median age B01002 | 40.9 | 40.3 | 39.0 |
| Under 18 B01001 | 21.8% | 22.0% | 22.3% |
| 65 and over B01001 | 21.5% | 19.1% | 17.9% |
| Households B11001 | 4,747 | 413,849 | 2,508,227 |
| Foreign born B05002 | 13.9% | 8.4% | 4.5% |
| Median household income B19013 | $72,005 | $82,936 | $70,702 |
| Median family income B19113 | $83,153 | $110,950 | $91,360 |
| Per capita income B19301 | $39,809 | $51,977 | $39,695 |
| Poverty rate B17001 | 11.5% | 9.8% | 12.6% |
| Unemployment rate B23025 | 3.2% | 4.3% | 4.0% |
| Civilian labor force B23025 | 5,774 | 521,387 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.2 | 23.1 | 23.5 |
| Bachelor's degree or higher B15003 | 36.0% | 47.4% | 32.4% |
| Housing units B25001 | 5,066 | 446,192 | 2,825,287 |
| Owner-occupied B25003 | 63.1% | 69.2% | 68.1% |
| Renters B25003 | 36.9% | 30.8% | 31.9% |
| Median home value B25077 | $237,700 | $276,800 | $230,300 |
| Median gross rent B25064 | $1,172 | $1,209 | $1,033 |
| White, not Hispanic B03002 | 55.8% | 61.4% | 76.3% |
| Black B03002 | 23.7% | 24.0% | 10.9% |
| Hispanic or Latino B03002 | 13.8% | 3.9% | 5.2% |
| Asian B03002 | 2.7% | 4.9% | 2.1% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bridgeton, MO.
Comments